A MOTHER from Ashton has been speaking about why she is taking part in Greater Manchester’s first Covid-19 vaccine trial.
Sarah, 43, whose surname has not been revealed, is part of the study to test the safety and effectiveness of a new vaccine, developed by US biotechnology company Novavax.
She said: “I have a young family and obviously the current situation has really changed the way we live, so I am really keen to do anything that will help everyone out of this situation.
“When I arrived, Dr Baxter [the lead researcher on the trial at Stockport] sat everyone down and explained the process and talked about how the vaccine trials work. He explained that this is phase three and what that means. There was an opportunity to ask questions and it was a really good process.
“We were in a group of seven [for the initial introductory session] and it was a really open opportunity to ask anything we were concerned about. All the way through, when I met the doctor and the nurse at the next stages, that was the same.
“It’s been a really pleasant experience despite there being needles involved. I did worry a little bit, but it’s been fine.”
Stockport NHS Foundation Trust was the first site in Greater Manchester selected to undertake the Novavax study. Almost 750 volunteers from Stockport, South East Manchester and East Cheshire areas are taking part in the trial, which closed to new participants this week. A total of 15,000 volunteers are taking part nationally.
Around 140 members of NHS staff from across Greater Manchester have been working on carrying out this study at a community sports club, supporting Stockport NHS Foundation Trust as part of a large-scale collaborative effort.
This is the first in a number of phase three Covid-19 vaccine trials to be carried out in Greater Manchester, in co-operation with the National Institute for Health Research (NIHR).
Other Covid vaccine trials are currently taking place locally and more are due to be undertaken over the coming months, calling on volunteers who have signed up to the NHS Vaccine Registry. You can still sign up.
Phase three involves many thousands of people, giving researchers insights into the effects of a vaccine on a much larger population than phase one and two studies.
Dr David Baxter, principal investigator for the trial at Stockport NHS Foundation Trust, said: “We have had an absolutely tremendous response from the public in joining in our research trial. Establishing safe vaccines to combat Covid-19 has been one of the key medical challenges the world has faced in modern times, and people have been very keen to help our research team with this.
“I’d like to say a huge thank you to all our volunteers for their time, effort and support, and also acknowledge the considerable input from healthcare staff both in Stockport and from across Greater Manchester for their tireless work in the study.”